Vitamin D and other environmental risk factors in Colombian patients with multiple sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 16 10 2019
revised: 15 01 2020
accepted: 03 02 2020
pubmed: 23 2 2020
medline: 23 3 2021
entrez: 23 2 2020
Statut: ppublish

Résumé

The aim of this study was to explore the association between MS and vitamin D levels, as well as Epstein-Barr virus (EBV) seropositivity and smoking history in a Colombian population. We conducted a cross-sectional study between 2017 and 2018. We measured vitamin D levels and EBV antibody titers and administered a questionnaire to assess dietary habits, smoking, second-hand smoking and duration of smoking, sunlight exposure, physical activity, and personal and family history in individuals with and without multiple sclerosis during adolescence. A multivariable logistic regression model was then performed to explore the association between vitamin D status and MS. A total of 87 individuals with MS (mean age 40.9 years; 65.52% females) and 87 without MS (mean age 55 years; 65.52% females) were included in the analysis. In the multivariable analysis, after controlling for supplementation vitamin D levels did not differ between both groups and no difference was found regarding tobacco smoke exposure. The proportion of individuals who tested positive for anti-EBV nuclear antigen was significantly higher in individuals with MS (95.4% vs 82.76%, p = 0.028) CONCLUSION: : We did not find a statistically significant association between MS and vitamin D levels while anti-EBV nuclear antigen titers behaved as previously described in the literature. This study provides new evidence of the association between MS and different risk factors in our country, reinforcing the hypothesis that the pathogenesis of MS is multifactorial. Further studies are needed to better define the association between environmental factors and the development of MS in low prevalence areas.

Identifiants

pubmed: 32086164
pii: S2211-0348(20)30059-6
doi: 10.1016/j.msard.2020.101983
pii:
doi:

Substances chimiques

Epstein-Barr Virus Nuclear Antigens 0
Vitamin D 1406-16-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101983

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest J. Toro is an associate editor of NEJM Journal Watch Neurology and is an editorial board member for Multiple Sclerosis and Related Disorders. L. Burbano, S. Reyes, D. F. Cuellar-Giraldo, A. Duque, M. I. Reyes-Mantilla, C. Torres, J. Ríos, J. S. Rivera, F. Cortés, J. Patiño, and D. Noriega report no disclosures.

Auteurs

Jaime Toro (J)

Department of Neurology, Hospital Universitario-Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia; Universidad El Bosque, Carrera 7B Bis No. 132-11, Bogotá, Colombia; School of Medicine, Universidad de Los Andes, Carrera 1 No. 18A-12, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia. Electronic address: jtoro@uniandes.edu.co.

Saúl Reyes (S)

Universidad El Bosque, Carrera 7B Bis No. 132-11, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Camilo Díaz-Cruz (C)

School of Medicine, Universidad de Los Andes, Carrera 1 No. 18A-12, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Lisseth Burbano (L)

Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

David Felipe Cuéllar-Giraldo (DF)

Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Alejandra Duque (A)

Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

María I Reyes-Mantilla (MI)

Universidad El Bosque, Carrera 7B Bis No. 132-11, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Camilo Torres (C)

School of Medicine, Universidad de Los Andes, Carrera 1 No. 18A-12, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Jorge Ríos (J)

School of Medicine, Universidad de Los Andes, Carrera 1 No. 18A-12, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Juan Sebastián Rivera (JS)

School of Medicine, Universidad de Los Andes, Carrera 1 No. 18A-12, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Fabián Cortés-Muñoz (F)

Universidad El Bosque, Carrera 7B Bis No. 132-11, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia; Fundación Clínica Shaio, Bogotá, Colombia.

Jorge Patiño (J)

Department of Neurology, Hospital Universitario-Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Daniel Noriega (D)

Department of Neurology, Hospital Universitario-Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia; Multiple Sclerosis and other Neurological Disorders Research Group, Fundación Santa Fé de Bogotá, Carrera 7 No. 117-15, Bogotá, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH